CAR-T therapies and cancer risk: No easy answers for the FDA
Share this article While there is potential for correlation, there is not enough information to infer any causation, says Dr, Bruce Levine, professor at the
Share this article While there is potential for correlation, there is not enough information to infer any causation, says Dr, Bruce Levine, professor at the
When Kristy Uddin, 49, went in for her annual mammogram in Washington state last year, she assumed she would not incur a bill because the
Those pandemic puppies are growing up to be a public health concern.
Share this article Atossa Therapeutics’ CEO discussed updates for its breast cancer program. Credit: NDAB Creativity via Shutterstock Atossa Therapeutics estimates a Q3 readout of
The Dales Report is here with a psychedelics exclusive podcast. In this episode of Trade To Black with CEO Doug Drysdale, we catch up with
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal
Share this article Patients aged 1–11 years and weighing at least 15kg with the oesophageal allergic inflammation will now have access to the drug. Credit:
Share this article Sparsentan received accelerated approval by the US Food and Drug Administration (FDA) to reduce proteinuria in adults with primary IgA nephropathy. Credit: